Hallucinations and psychosis in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 4, 2009, Pages

  Rabey, Josè Martin ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Hallucinations Delusions; Non motor symptoms in PD; Psychosis in Parkinson's disease

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PIMAVANSERIN; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SEROTONIN 2A AGONIST; TRYPTOPHAN; ZOTEPINE;

AGRANULOCYTOSIS; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DELIRIUM; DELUSION; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SYNTHESIS; HALLUCINATION; HUMAN; INTRARATER RELIABILITY; LOW DRUG DOSE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOPATHY; PSYCHOSIS; QUALITY OF LIFE; RECURRENT DISEASE; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; ANIMAL; COMPLICATION; HALLUCINATIONS; PSYCHOLOGY; PSYCHOTIC DISORDERS; TIME;

ANIMALS; ANTIPARKINSON AGENTS; HALLUCINATIONS; HUMANS; PARKINSON DISEASE; PREVALENCE; PSYCHOTIC DISORDERS; TIME FACTORS;

EID: 72649097167     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70846-6     Document Type: Article

References (63)

1. Papapetropoulos S., and Mash D.C. Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol 252 (2005) 753-764
2. Factor S.A., Molho E.S., Podaskalny G.D., and Brown D. Parkinson's Disease: Drug Induced Psychiatric states. In: Weiner W.J., and Lang A.E. (Eds). Behavioral Neurology of Movement Disorders. Advances in Neurology Vol. 65 (1995), Raven Press Ltd, New York, NY 115-138
3. Thanvi B.R., Lo T.C., and Harsh D.P. Psychosis in Parkinson's disease. Postgrad Med J 81 (2005) 644-646
4. Voon V., and Fox S.H. Medication-related impulse control and repetitive behaviors in Parkinson's disease. Arch Neurol 64 (2007) 1089-1096
5. Inzelberg R., Kipervasser S., and Korczyn A.D. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 64 (1998) 533-535
6. Ravina B., Marder K., Fernandez H.H., Friedman J.H., McDonald W., Murphy D., et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 22 (2007) 1061-1068
7. Onofrj M., Bonanni L., Albani G., Mauro A., Bulla D., and Thomas A. Visual hallucinations in Parkinson's disease: clues to separate origins. J Neurol Sci 248 (2006) 143-150
8. Aarsland D., Larsen J.P., Cummins J.L., and Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease: a community-based study. Arch Neurol 56 (1999) 595-601
9. Holroyd S., Currie L., and Wooten G.F. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 70 (2001) 734-738
10. Fénelon G., Mahieux P., Huon R., and Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123 (2000) 733-745
11. Schwab R.S., Fabing H.D., and Prichard J.S. Psychiatric symptoms and syndromes in Parkinson's disease. Am J Psychiatry 107 (1951) 901-907
12. Celesia G.G., and Wanamaker W.M. Psychiatric disturbances in Parkinson's disease. Dis Nerv Syst 33 (1972) 577-583
13. Fénelon G., Goetz C.G., and Karenberg A. Hallucinations in Parkinson's disease in the prelevodopa era. Neurology 66 (2006) 93-98
14. Fernandez H., and Friedman J. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs 11 (1999) 467-483
15. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005) 1863-1872
16. Paulsen J.S., Salmon D.P., Thal L.J., Romero R., Weisstein-Jenkins C., Galasko D., et al. Incidence of and risk factors for hallucinations and dementia in patients with probable AD. Neurology 54 (2000) 1965-1971
17. Goetz C.G., and Stebbins G.T. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43 (1993) 2227-2229
18. Aarsland D., Larsen J.P., Tandberg E., and Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 48 (2000) 938-942
19. Goetz C.G., and Stebbins G.T. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45 (1995) 669-671
20. Hely M.A., Morris J.G., Reid W.G., and Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20 (2005) 190-199
21. Sanchez-Ramos J.R., Ortoll R., and Paulson G.W. Visual hallucinations associated with Parkinson disease. Arch Neurol 53 (1996) 1265-1268
22. Marsh L. Psychosis in Parkinson's Disease. Curr Treat Options Neurol 6 (2004) 181-189
23. Friedman J., and Fernandez H. The non-motor problems of Parkinson's disease. Neurologist 6 (2000) 18-27
24. Comella C.L., Tanner C.M., and Ristanovic R.K. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 34 (1993) 710-714
25. Graham J.M., Grünewald R.A., and Sagar H.J. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 63 (1997) 434-440
26. Goetz C.G. Hallucinations in Parkinson's disease: the clinical syndrome. Adv Neurol 80 (1999) 419-423
27. Golden W.E., Lavender R.C., and Metzer W.S. Acute postoperative confusion and hallucinations in Parkinson disease. Ann Intern Med 111 (1989) 218-222
28. Rabey J.M., Vardi J., Ashkenazi J.J., and Streifler M. L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients. Gerontology 23 (1977) 438-444
29. Factor S.A., and Molho E.S. Threatening auditory hallucinations and Cotard syndrome in Parkinson disease. Clin Neuropharmacol 27 (2004) 205-207
30. Marsh L., Williams J.R., Rocco M., Grill S., Munro C., and Dawson T.M. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 63 (2004) 293-300
31. Fénelon G., Thobois S., Bonnet A.M., Broussolle E., and Tisson F. Tactile hallucinations in Parkinson's disease. J Neurol 249 (2002) 1699-1703
32. Chou K.L., Messing S., Oakes D., Feldman P.D., Breier A., and Friedman J.H. Drug induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 28 (2005) 215-219
33. Klawans H. Levodopa-induced psychosis. Psychiatr Ann 8 (1978) 447-471
34. Williams D.R., Warren J.D., and Lees A.J. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry 79 (2008) 652-655
35. Juncos J.L., Robert V.J., Evatt M.L., Jewart R.D., Wood C.D., Potter L.S., et al. Quetiapine improves psychotic symptoms in Parkinson's disease. Mov Disord 19 (2004) 29-35
36. Factor S.A., Brown D., Molho E.S., and Podskalny G.D. Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 44 (1994) 544-546
37. Fernandez H.H., Aarsland D., Fénelon G., Friedman J.H., Marsh L., Tröster A.I., et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord 23 (2008) 484-500
38. Overall J.E., and Gorham D.R. The brief psychiatric rating scale. Psychol Rep 10 (1962) 799-812
39. Friedman J.H., and Lannon M.C. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 39 (1989) 1219-1221
40. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340 (1999) 757-763
41. Rabey J.M., Prokhorov T., Miniovitz A., Dobronevsky E., and Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 22 (2007) 313-318
42. Nicholson I.R., Chapman J.E., and Neufeld R.W. Variability in BPRS definitions of positive and negative symptoms. Schizophr Res 17 (1995) 177-185
43. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale (BPRS) recent development in ascertainment and scaling. Psychopharmacol Bull 24 (1988) 97-99
44. Mohr E., Mendis T., Hildebrand K., and De Deyn P.P. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 15 (2000) 1230-1237
45. Fernandez H.H., Trieschmann M.E., and Okon M.S. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord 20 (2005) 104-105
46. Andreasen N.C. Scale for the assessment of positive symptoms (SAPS) (1984), University of Iowa, Iowa city, Iowa
47. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., and Gorbein J. The Neuropsychiatry Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
48. Aarsland D., Larsen J.P., Lim N.G., Janvin C., Karlsen K., Tandberg E., et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 67 (1999) 492-496
49. Friedberg G., Zoldan J., Weizman A., and Melamed E. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 21 (1998) 280-284
50. Visser M., Verbaan D., van Rooden S.M., Stiggelbout A.M., Marinus J., and van Hilten J.J. Assessment of psychiatric complications in Parkinson's Disease: The SCOPA-PC. Mov Disord 22 (2007) 2221-2228
51. Dodd M.L., Klos K.J., Bower J.H., Geda Y.E., Josephs K.A., and Ahlskog J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62 (2005) 1377-1381
52. Giovannoni G., O'Sullivan J.D., Turner K., Manson A.J., and Lees A.J. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68 (2000) 423-428
53. Lesieur H.R., and Blume S.B. The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gambling. Am J Psychiatry 144 (1987) 1184-1188
54. Guy W. ECDEU assessment manual for psychopharmacology. DHEW publication no. (ADM) 76-338. Rockville, MD: US Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; 1976. p. 217-22.
55. French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 353 (1999) 2041-2042
56. Morgante L., Epifanio A., Spina E., Zappia M., Di Rosa A.E., Marconi R., et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27 (2004) 153-156
57. Miyasaki J.M., Shannon K., Voon V., Ravina B., Kleiner-Fisman G., Anderson K., et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (2006) 996-1002
58. Rabey J.M., Treves T.A., Neufeld M.Y., Orlov E., and Korczyn A.D. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 45 (1995) 432-434
59. Klein C., Gordon J., Pollak L., and Rabey J.M. Clozapine in Parkinson's disease psychosis: a 5-year follow-up review. Clin Neuropharmacol 26 (2003) 8-11
60. Pollak P., Tison F., Rascol O., Destée A., Péré J.J., Senard J.M., et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75 (2004) 689-695
61. Weiner D.M., Vanover K.E., Brann M.R., Meltzer H.Y., and Davis R.E. Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics. Curr Opin Investig Drugs 4 (2003) 815-819
62. McKeith I., Del Ser T., Spano P., Emre M., Wesnes K., Anand R., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356 (2000) 2031-2036
63. Kurlan R., Cummings J., Raman R., Thal L., and Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 68 (2007) 1356-1363